Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Non-Current Debt (2024 - 2025)

bioAffinity Technologies (BIAF) has disclosed Non-Current Debt for 2 consecutive years, with $43658.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt rose 101.38% to $43658.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $43658.0, a 101.38% increase, with the full-year FY2024 number at $20180.0, changed N/A from a year prior.
  • Non-Current Debt was $43658.0 for Q3 2025 at bioAffinity Technologies, down from $45952.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $48156.0 in Q1 2025 to a low of $20180.0 in Q4 2024.